GT Biopharma (GTBP) investor relations material

Proprietary TriKE® platform and technology

• TriKE® platform uses camelid nanobody technology to create tri-specific NK cell engagers for targeted cancer and autoimmune disease therapy.

• TriKE®s activate NK cells via CD16A and IL-15, targeting tumor antigens for enhanced killing with potentially less toxicity than T-cell therapies.

• Modular design allows targeting of multiple tumor-associated antigens, including B7H3, HER2, CD33, PDL1, and CD19.

• Second-generation TriKE®s (e.g., GTB-3650, GTB-5550) utilize camelid nanobodies for improved potency and manufacturing.

Clinical pipeline and development progress

• GTB-3550 demonstrated proof of concept in Phase 1 for AML/MDS, showing NK cell activation, proliferation, and significant blast reduction in several patients.

• GTB-3650 (AML/MDS) and GTB-5550 (solid tumors) are advancing, with INDs accepted and clinical trials scheduled for 2025–2026.

• GTB-7550 is in preclinical development for lupus and other autoimmune diseases, targeting CD19 for B-cell depletion.

• Over six pipeline assets are in preclinical development, covering both solid and hematological malignancies.

Competitive differentiation and safety profile

• TriKE®s co-stimulate CD16 and IL-15, providing NK cell-specific proliferation with less bystander T-cell activity and reduced cytokine release syndrome.

• Demonstrated minimal clinically significant toxicity in clinical trials, with only mild, manageable CRS observed.

• Nanobody-based TriKE®s offer improved binding affinity and commercial manufacturing advantages.